Showing 641-650 of 5061 results for "".
- Increased Adherence, Symptom Improvement Seen When Psoriasis Patients Switch to IL-17 Blockershttps://practicaldermatology.com/news/increased-adherence-symptom-improvement-seen-when-psoriasis-patients-switch-to-il-17-blockers/2460147/New data points to increased adherence and improvement in symptoms for psoriasis patients who switch to interleukin-17 inhibitors. The study, which was conducted with Walgreens, a parent company of AllianceRx Walgreens Prime, was presented at the National Association of Specialty Pharma
- Ortho Derm Gets NDA for IDP-123 Lotion for Acnehttps://practicaldermatology.com/news/ortho-derm-gets-nda-for-idp-123-lotion-for-acne-1/2460121/The U.S. Food and Drug Administration (FDA) has accepted Ortho Dermatologic’s New Drug Application for IDP-123 (tazarotene 0.045%) Lotion or acne with a PDUFA action date of Dec. 22, 2019. If approved, IDP-123 will be the first taza
- Complete Wound Healing Seen on Index Lesion of the First Subject in an Ongoing Phase 2 Trial of RGN-137 Dermal Gel for EBhttps://practicaldermatology.com/news/complete-wound-healing-seen-on-index-lesion-of-the-first-subject-in-an-ongoing-phase-2-trial-of-rgn-137-dermal-gel-for-eb/2460118/Lenus Therapeutics, LLC, a US-based joint venture between GtreeBNT and Yuyang DNU in Korea, has confirmed complete wound healing of the index lesion of the first subject enrolled in its ongoing single-masked Phase 2 clinical trial with RGN-137 dermal gel for Epidermolysis Bullosa (EB).
- Novartis Offers Free Genetic Testing for Advanced Melanomahttps://practicaldermatology.com/news/novartis-offers-free-genetic-testing-for-advanced-melanoma/2460095/The Know Now Testing Program is an initiative from Novartis in collaboration with Quest Diagnostics that offers genetic mutation testing at no cost for all patients with stage III or stage IV melanoma. Nearly half of all advanced melanoma patients carry a specific mutation, called BRAF.
- Report: Dermavant Files for $100M IPOhttps://practicaldermatology.com/news/report-dermavant-files-for-100m-ipo/2460043/Dermavant Sciences last week filed with the SEC to raise up to $100 million in an initial public offering, Renaissance Capital reports.
- Happy 10th Birthday Dysport!https://practicaldermatology.com/news/happy-10th-birthday-dysport/2460015/Galderma Laboratories’ Dysport (abobotulinumtoxinA) is ringing in its 10th birthday. To celebrate this milestone, Galderma is offering double points for Dysport aesthetic treatments registered in the ASPIRE Rewards program through July 31
- Stelatopia Emollient Face Cream Now Available from Mustelahttps://practicaldermatology.com/news/stelatopia-emollient-face-cream-now-available-from-mustela/2459902/Mustela Stelatopia Emollient Face Cream is now available, specifically designed for extremely dry to eczema-prone skin and gentle enough to use on newborns. Formulated with Avocado Perseose®, which is intended to restore and protect the skin barrier by boosting ceramides a
- Applied Biology to Enter into a License Agreement with Hairmore for Novel Traction Alopecia Rxhttps://practicaldermatology.com/news/applied-biology-to-enter-into-a-license-agreement-with-hairmore-for-novel-traction-alopecia-rx/2459904/Applied Biology, Inc. is bringing its novel TAAR receptor agonist for the treatment of traction or ponytail alopecia to the Chinese market through a licensing deal with the Hairmore Group. When applied to the scalp, Applied Biology’s
- Almirall's Seysara Now Availablehttps://practicaldermatology.com/news/seysara-now-available/2459932/SeysaraTM (sarecycline), a novel tetracycline-derived oral antibiotic developed specifically for the treatment of acne, is now commercially available from Almirall. Seysara™ was approved in October by FDA for the treatment of moderate to severe non-nodular inflammatory acne
- Novan: Top Line Phase 2 Data Positive for SB206 Gel for Molluscumhttps://practicaldermatology.com/news/novan-top-line-phase-2-data-positive-for-sb206-gel-for-molluscum/2457507/Top line results from Novan’s Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum are promising. Data for three full cohorts of four show that SB206 gel demonstrated a clear treatment effect on the complete clearance of